ClinicalTrials.gg
RecruitingNCT07560852ENDOLIFEUpdated May 26, 2026

Impact of Endotest on Patients' Quality of Life: a Cohort Study

An observational study in Patient With a Prescribed Endotest and Endometriosis (Diagnosis), sponsored by ZIWIG. Recruiting at 7 sites in France. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by ZIWIG · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years to 43 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.

Planned enrollment
2nd of 58
20,000 · median 133
Started
2026
with 14 others
Observational
58 of 128
23 open now
Primary completion
2029-07
later than 50 of 55 live
Registered
121st of 128
by date
Lead sponsor
6 of 128
ZIWIG

Among the 128 studies in Endometriosis with a site in France, this one is the 2nd largest by planned enrollment of the 58 observational ones that give a count, is one of 15 that started in 2026, is one of 58 observational ones, reaches primary completion later than 50 of the 55 other live ones, and was the 121st registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 43 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometriosis with a site in France, or all of them as a file.
02

Study summary

Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022. Since February 2025, several French clinical investigation sites have been offering Endotest, developed by Ziwig, under the innovation funding. Initially, this innovation funding enabled 2,500 patients to be included in a clinical trial (ENDOBEST: ID-RCB 2024-A02092-45). Since the end of December 2025, it has been expanded and now covers a further 22,500 patients whose are not included in the trial. This medical device is based on Next-Generation Sequencing combined with analytical algorithms and enables the identification of endometriosis from a saliva sample. This non-invasive test aims to improve patient care by reducing diagnostic delays and guiding treatment strategies.

Despite the available data on its diagnostic performance, the impact of Endotest on patients' quality of life, their emotional experience, their coping strategies, and their care pathways remains insufficiently documented. Indeed, the Endotest result (positive or negative) can significantly influence these various aspects. This cohort study aims to assess the impact of Endotest on patients' quality of life, primarily using validated self-report questionnaires and clinical data from medical records. By including a large sample of patients, this study aims to provide robust and generalisable data that will be useful for clinicians and patients themselves.

03

Conditions studied

  • Patient With a Prescribed Endotest
  • Endometriosis (Diagnosis)

Keywords

  • endometriosis
04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with endometriosis for whom an Endotest is prescribed

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with a prescription for Endotest
  • Women aged 18 to 43
  • Who have dated and signed the consent form
  • Affiliated with the French healthcare system or covered by health insurance abroad

Exclusion criteria

Exclusion Criteria:

  • for the use of Endotest:

    1. Current pregnancy;
    2. Medical history of cancer or infection;
    3. Active infection at the time of saliva collection;
  • Significant difficulty reading and understanding the language of the country in which the participant is located.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Target follow-up
16 Months
Patient registry
Yes

Groups and cohorts

  • Endometriosis cohort performing Ziwig ENDOTEST®

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    EHP 5+6, RAND-36 et 6 and 12 months follow-up visits

06

What researchers measure

Primary outcomes

  1. To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.

    Endometriosis-specific quality of life score on the EHP-5 + 6 questionnaire (Endometriosis Health Profile - 11 items). Score goes from 0 to 44. Higher the score is, worse the outcome is.

    Time frame: Day 1, 6 months and 12 months.

  2. To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.

    Score for each of the 8 dimensions of quality of life on the RAND-36 questionnaire (declined version of the 36-Item Short Form Survey (SF-36)) Score goes from 0 to 100 for each ones of the 8 dimensions. Higher the score is, better the outocome is.

    Time frame: Day 1, 6 months and 12 months

  3. To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.

    Factors associated with the level of endometriosis-specific quality of life (EHP-5+6 (Endometriosis Health Profile - 11 items)) at 6 months. Score goes from 0 to 44. Higher the score is, worse the outcome is.

    Time frame: 6 months

  4. To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.

    Factors associated with the level of each of the 8 dimensions of general quality of life (RAND-36 (declined version of the 36-Item Short Form Survey (SF-36)) at 6 months. Score goes from 0 to 100 for each ones of the 8 dimensions. Higher the score is, better the outocome is.

    Time frame: 6 months

Secondary outcomes

  1. Describe the impact of Endotest on adaptation strategies.

    Brief-COPE score (Brief Coping Orientation to Problems Experienced) Score goes from 1 to 4 for the 3 subscales (Problem Focussed, Emotion Focussed, Avoidant) There is no direct correlation between higher/lower scores and better/worse outcomes

    Time frame: 6 months

  2. Describe the impact of Endotest on the assisted reproductive technology (ART) journey (including infertility assessment and fertility preservation).

    Number of patients starting an assisted reproductive technology (ART) treatment programme

    Time frame: Through study completion, an average of 1 year

  3. Describe the impact of Endotest on the assisted reproductive technology (ART) journey (including infertility assessment and fertility preservation).

    Number of patients for whom the ART treatment plan is amended (e.g. switching from intrauterine insemination to IVF, surgery)

    Time frame: Through study completion, an average of 1 year

  4. Describe the impact of Endotest's results immediately following the announcement.

    Personalised questionnaire on immediate emotional reactions

    Time frame: 1 month

  5. Describe the impact of Endotest on patient care: tests, treatments, and additional procedures (e.g., laparoscopy).

    Number and type of additional tests or procedures performed (ultrasound, MRI, laparoscopy, etc.).

    Time frame: Through study completion, an average of 1 year

  6. Describe the impact of Endotest on patient care: tests, treatments, and additional procedures (e.g., laparoscopy).

    Initiation or modification of treatments (hormonal, pain relievers, etc.).

    Time frame: Through study completion, an average of 1 year

  7. To assess the impact of Endotest on anxiety levels.

    Visual Analog Scale Anxiety Score Score goes from 0 to 100 Lower the score is, better the outcome is

    Time frame: 1 month

  8. Compare the care provided to patients with a positive Endotest result across participating countries.

    Type of coverage and waiting period

    Time frame: Through study completion, an average of 1 year

  9. Compare pelvic sensitivity based on Endotest results

    Convergences Score for Pelvic-Perineal Pain Score goes from 0 to 10 Lower the score is, better the outcome is.

    Time frame: Day 1 and 12 months

07

Study locations

1 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jul 2029, 38 months after the start.

Of 185 observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
May 1, 2026
StartActual
May 6, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07560852
Lead sponsor
ZIWIG
Collaborators
Monitoring Force Group
Responsible party
Sponsor
First posted
May 1, 2026
Start date
May 6, 2026
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
May 26, 2026

Study contacts

Fabien Le Floc'h, Project Manager
Contact
fabien.lefloch@monitoring-force.fr
+330630447709

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion